Treating the plaques that contribute to the worldwide leading causes of death is now a possibility.

Corvida™, in development to be a Best-in-Class, orally administered adjunct to statin therapy indicated to treat atherosclerosis by targeting high-risk, vulnerable plaques.
Corvida™ significantly reduced arterial plaque in the ApoE-/- mouse model in a study conducted at The Cleveland Clinic:  Aortic Sinus lesion area reduced by 45%, p< 0.001 and Aortic Lesion (%) reduced by 67%, p< 0.001 .